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Abstract
Bone morphogenetic protein-2 (BMP-2) is considered a promising adjuvant for the treatment of skeletal non-union
and spinal fusion. However, BMP-2 delivery in a conventional collagen scaffold necessitates a high dose to achieve
an efficacious outcome. To lower its effective dose, we precomplexed BMP-2 with the glycosaminoglycans (GAGs)
dermatan sulfate (DS) or heparin (HP), prior to loading it into a hyaluronic acid (HA) hydrogel. In vitro release studies
showed that BMP-2 precomplexed with DS or HP had a prolonged delivery compared to without GAG. BMP-2-DS
complexes achieved a slightly faster release in the first 24 h than HP; however, both delivered BMP-2 for an equal
duration. Analysis of the kinetic interaction between BMP-2 and DS or HP showed that HP had approximately 10
times higher affinity for BMP-2 than DS, yet it equally stabilized the protein, as determined by alkaline phosphatase
activity. Ectopic bone formation assays at subcutaneous sites in rats demonstrated that HA hydrogel-delivered
BMP-2 precomplexed with GAG induced twice the volume of bone compared with BMP-2 delivered uncomplexed to
GAG.
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Introduction
Worldwide, patients continue to suffer from bone non-unions.
Gold standard treatment relies on the continued use of
autologous bone graft obtained from the patient’s own iliac
crest [1]. This bone source has a limited quantity and the
quality is dependent on the individual patient, which reduces its
therapeutic potential [2]. Thus, bone repair by tissue
engineering systems has attracted broad attention. Despite the
continuing development of hormones and other bone-
stimulating molecules, bone morphogenetic proteins (BMPs)
remain the most potent inducers of bone formation in vivo [3].
In particular, BMP-2 is widely recognized to be one of the most
powerful osteoinductive factors for bone regeneration [4,5] and
was originally identified as a factor in bone tissue that in
extracted form could stimulate bone formation when added
exogenously to an extraosseous site [6]. Moreover, human
recombinant BMP-2 [7], has proven to be highly efficient as a
bone-inducing adjuvant in animals.
Endogenous BMP-2 is also important for normal bone
homeostasis and is upregulated immediately following bone
trauma [8] and actively contributes to the recruitment,
proliferation and differentiation of osteoprogenitor cells during
the bone healing process [9]. In the clinical setting, BMP-2
absorbed into a bovine collagen type I sponge has proven to
be effective in the treatment of degenerative disc disease
(spinal fusion) and fracture non-union [10,11]. However,
excessive dosing has been associated with adverse events
that include tissue edema and ossification at undesired sites
[12,13]. There is also concern because the systemic half-life of
BMP-2 is short and FDA-approved delivery is reliant on a
collagen sponge with low affinity for BMP-2 [14], so requiring
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supra-physiological doses in order to achieve an efficacious
outcome [15].
Recent evidence by our group and others [16,17] suggests
that BMP-2-induced bone formation is largely dependent on
stability of BMP-2 and its release kinetics, with a controlled
release enhancing the effect. Long-term BMP-2 delivery
increases bone-healing rates compared with short-term
delivery at an equal dose [18,19]. As a consequence, a number
of delivery strategies aimed at improving BMP-2 dose-
effectiveness have been developed. Our group, along with
others, has shown that hyaluronic acid (HA) hydrogels are
suitable for bone tissue engineering applications [20-23]. HA is
a natural extracellular matrix glycosaminoglycan (GAG) that
regulates several biological processes, including cell migration,
proliferation, differentiation and wound healing [24]. In vivo, HA
is degraded by the action of oxygen free radicals [25] and
hyaluronidases [26,27]. Also, HA hydrogels are non-
immunogenic and have been successfully utilized as scaffolds
for BMP-2 delivery both in preclinical [20,28,29] and clinical
[13] trials. As an injectable device, HA permits in situ
administration in a minimally invasive manner [21,30]. Although
promising characteristics, HA hydrogels share a problem with
many similar materials, namely insufficient control of BMP-2
release. This is because many hydrogels rapidly releases
BMP-2 through a passive diffusion mechanism [28]. Although
BMP-2 could be covalently linked to this polymeric scaffold [31]
such a chemical modification may compromise BMP-2 activity.
Also, electrostatic immobilization of BMP-2 on a basement
membrane proteoglycan (perlecan domain I) covalently
conjugated to a HA hydrogel has been attempted [32].
However this strategy whilst sustaining the release of active
BMP-2, is limited by the elaborated multi-step bioconjugation.
In the present study we aim to optimize the delivery of
BMP-2 from an HA hydrogel through the simple addition of a
natural extracellular matrix (ECM) glycosaminoglycan (GAG).
Previous reports have shown that the incorporation of GAGs,
such as heparin (HP), in a polymer carrier significantly
improves BMP-2-mediated bone formation [33,34].
Surprisingly, little information has been published regarding the
role that other GAGs play in mediating BMP-2 activity, although
this is rapidly gaining interest among researchers. Dermatan
sulfate (DS), also known as chondroitin sulfate B, has be
shown to interact with and mediate the activity of HGF [35],
FGF-2 and PDGF [36]. However, to date little is known of a role
for DS in BMP-2-induced osteogenesis. To address this, we
investigated how DS influences BMP-2 activity compared with
HP. We then went on to assess whether DS improved the in
vivo bone forming capacity of BMP-2. Our strategy was to pre-
complex BMP-2 with either DS or HP prior to loading it into the
HA hydrogel and to compare the in vitro release of BMP-2.
Next, we characterized the interactions between BMP-2 and
DS or HP by surface plasma resonance (SPR) to study non-
covalent interactions and to measure the affinity constant.
Then, using an alkaline phosphatase activity assay, we
determined whether the BMP-2 released from the constructs
was bioactive. Finally, we assessed gel constructs in a
subcutaneous rat model for ectopic bone formation using
micro-CT, scanning electron microscopy (SEM), histology and
immunohistochemistry (IHC).
Results
1: Construct preparation
While preparing the constructs for bone engineering, we first
precomplexed BMP-2 with DS or HP at a 1:5 ratio and then
loaded the complex into the HA hydrogel scaffold (Figure S1).
The gel was formed within 1 min by mixing all components in a
dual syringe system. The mixing triggered a spontaneous
cross-linking reaction of the two polymers with complementary
reactive functionalities under neutral aqueous conditions. The
advantage of BMP-2 precomplexation with heparin has been
demonstrated in a scaffold loaded with BMP-2. In a study by
Johnson et al., BMP-2 precomplexed with HP prior to adding a
collagen carrier yielded 20% more bone formation in a femoral
defect model compared with BMP-2 adsorbed into collagen
with incorporated HP [37][. Bramono et al. found that a
BMP-2:HP ratio of 1:5 was the most favorable for enhancing
ectopic bone formation [38]; therefore, we used this proportion
in our study as well.
2: In vitro BMP-2 release kinetics and bioactivity.  To
evaluate the extent to which BMP-2 premixed with DS or HP
could delay the release of BMP-2 from the HA hydrogel
through affinity binding interactions, we performed an in vitro
release study over 30 days. The amount of BMP-2 released
from all constructs was first determined using an ELISA, and
the biological activity of the constructs was examined via the
ALP assay (Figure 1). We are aware that the protein is
sensitive and could easily absorb to the vial surface and form
aggregates in the release medium [39]. Therefore, to avoid
erroneous results that could be due to the dilution of BMP-2, at
each time point, the result was compared with the result
obtained from the incubation of free BMP-2 at an adequate
concentration (control). Furthermore, we measured the amount
of protein that was retained in the constructs after 30 days
(Figure 1B). The cumulative release consisted of two phases:
an initial release lasting up to 24 h (Figure 1A2) and a
subsequent, slower release lasting up to the 30th day (Figure
1A1). There was a clear difference in the initial release profile
between the constructs. The most rapid release was observed
in the HA hydrogel loaded with only BMP-2. From 6h up to 24h
we observed significant difference in the amount of BMP-2
released from gel/BMP-2 with DS compared to gel with only
BMP-2 (p<0,05). The HA hydrogels with BMP-2 premixed with
DS exhibited a larger initial release compared with the
construct containing HP. However, the further release of
BMP-2 from gel/BMP-2+DS and gel/BMP-2+HP remained
relatively constant and sustained over 30 days. The total final
release was 79% for DS and 75% for HP and was significantly
higher than the total final release from gel/BMP-2. In contrast;
the release from gel/BMP-2 reached a plateau after 7 days at
56% of the total release and did not increase much before the
end of the experiment.
To determine the amount of BMP-2 retained in the constructs
after 30 days, we digested constructs with a hyaluronidase
solution. We found that not all BMP-2 was released from the
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Figure 1.  In vitro release of BMP-2 from gel/BMP-2+DS, gel/BMP-2+HP and gel/BMP-2 over 30 days (A1) and over 24 h
(A2).  The amount of BMP-2 measured by ELISA is shown as the cumulative release normalized to the control release. (B) BMP-2
released/retained from the constructs after 30 days. (C) The bioactivity of BMP-2 released over 30 days as assessed by the ALP
activity of myoblast cells. The values represent the mean ± SD (n=3). Error bars represent the SD (n=3); *p<0.05 and **p<0.01.
doi: 10.1371/journal.pone.0078551.g001
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scaffolds by day 30 (Figure 1B). Approximately 15% of the
initial BMP-2 remained in both constructs loaded with
precomplexed BMP-2, while approximately 5% was found in
gel/BMP-2. Summing released and retained BMP-2 we found
that the part of BMP-2 loaded in the gels was lost. The amount
of retained BMP-2 was significantly higher in gel/BMP-2+DS or
HP compared to gel/BMP-2 (p<0.05). It might be due to
aggregation or adhesion to the storage tube surface upon
release experiment [20]. As expected, no BMP-2 was detected
from the HA hydrogels that were not loaded with BMP-2
(negative controls). Our observations of the release profile of
BMP-2 alone in the HA hydrogel were similar to those of our
previous studies. Accordingly, there was an initial burst release
of BMP-2 in the first 24 h and then almost a complete release
during the first week [39].
We then studied the biological activity of BMP-2 released
from constructs using ALP assays with the C2C12 cell line. In
the ALP activity assay only bioactive BMP-2 is able to trigger
differentiation of bone cells. The ALP activity of C2C12 cells did
not increase in the control supernatant obtained from the HA
hydrogel without BMP-2, and this result mirrored the result
obtained for cells cultured in media alone (negative control).
The addition of fresh BMP-2 to the culture medium enhanced
ALP activity (positive control). The ALP activity resulting from
the BMP-2 released from all constructs at each time point over
30 days is shown in Figure 2C. The HA hydrogel with
precomplexed BMP-2 demonstrated low ALP activity during the
1st week, followed by an increase during the 3rd and 4th weeks.
In contrast, the HA hydrogel without premixed BMP-2 exhibited
increased ALP activity during the first week that was reduced
during the 3rd and 4th weeks of the study.
3: BMP-2 binds to HP and DS
To understand the mechanism of BMP-2 release from the gel
construct, we examined the interactions between BMP-2 and
DS or HP at the molecular level using surface plasmon
resonance (Figure 2). A kinetic analysis of those interactions
was performed by injecting a concentration series of BMP-2
over immobilized DS (Figure 2A) or HP (Figure 2B). The
binding affinity, Kd, was calculated as the ratio of the
dissociation and association rate constants, kd/ka. The kinetic
data were fitted by the 1:1 Langmuir model. The interaction
with BMP-2 yielded an affinity constant, Kd, of 2±0.8 x 10-8 M
for the binding to DS and a Kd of 2.4±0.3 x10-9 M for the
binding to HP. An approximately three-fold slower association
and a three-fold faster dissociation explained the lower binding
affinity of BMP-2 for DS compared with that for HP.
4: In vivo bone efficacy
4.1: Bone volume analysis.  To determine the in vivo
efficacy of the constructs, the HA hydrogel containing BMP-2
precomplexed with DS or HP, containing BMP-2 only, or
without the protein was injected at subcutaneous sites in rats.
We injected a 200 µL volume of constructs containing HA
hydrogel with 4 µg of BMP-2 with or without 20 µg of HP or DS.
We used HA hydrogel alone as a negative control. The
constructs were prepared as described in section 3.1 (Figure
S1). No complications occurred after the surgical intervention,
and the animals remained in good health during the entire
study. After 6 weeks, rats were sacrificed, and ectopic bone
was harvested. All scaffolds containing BMP-2 induced bone,
while no evidence of ectopic bone formation or remaining gel
was detected in the groups injected with scaffolds lacking
protein. HA degradation did not result in any signs of an
inflammatory reaction or an influx of macrophages. The
ectopically formed bone tissue was rounded in shape and
firmly attached to the surrounding tissue. The ectopic bone
tissues were harvested, fixed and subjected to micro-CT
analysis using a pre-determined threshold of cortical bone for
direct clinical translation. The 3D and 2D reconstruction of a
representative sample from each group is shown in Figure 3A i-
iii. Micro-CT showed that BMP-2 precomplexed with DS or HP
significantly improved the potential of BMP-2 to induce bone
formation compared with the protein alone when the same
amount was delivered via the HA hydrogel. The quantitative
analysis revealed that the average volume of ectopic bone
Figure 2.  Kinetic analyses of BMP-2 binding to (A) dermatan sulfate (DS) and (B) heparin (HP).  Solid lines represent the
binding curves for six BMP-2 concentrations ranging from 0.2 to 50 nM. The dotted lines depict the result of a global fit of a 1:1
interaction model to the binding data. The binding affinity, Kd, was calculated as the ratio of the dissociation and association rate
constants, kd/ka. The study yielded an affinity constant, Kd, of 2.0±0.8 x 10-8 M for the binding of BMP-2 to DS and a Kd of 2.4±0.3
x10-9 M for the binding to HP. The standard deviation is based on the variation between duplicate experiments.
doi: 10.1371/journal.pone.0078551.g002
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formed at the site of the construct with GAGs was significantly
higher (p<0.5) than the volume of bone induced by the HA
hydrogel with only BMP-2 (Figure 3B). The volumes of ectopic
bone formed by gel/BMP-2+DS and gel/BMP-2+HP were 55
and 52 mm3, respectively, and were two-fold higher (p<0.05)
than the volume of bone generated by gel/BMP, which was 28
mm3. Furthermore, the mean trabecular thickness (Tb.Th.) was
significantly larger in ectopic bones formed by gel/BMP+DS or
HP compared to those induced by gel with only BMP-2 (Figure
3 C). However, the mean trabecular separation (Tb.Sp.) was
only slightly greater in ectopic bone areas formed by gel
containing BMP-2 and DS or HP than those induced by gel with
BMP-2 alone (Figure 3 D).
4.2: Bone structure.  The results of the micro-CT analysis
were further verified with standard histology and
immunohistochemistry (Figure 4). The same as 2D sections
from micro-CT (Figure 3A, lower row), the transverse sections
of ectopic bone stained with Masson’s Trichrome showed that
the bone was formed at the edges rather than in the center of
the sample. The central part of the sample was not filled with
bone tissue and the transversal sections appear as a ring. The
Figure 3.  Micro-CT analysis.  (A) 3D (upper row) and 2D
(lower row) image of the surface of ectopic bones formed 6
weeks post-injection of (i) gel/BMP-2+DS, (ii) gel/BMP-2+HP
and (iii) gel/ BMP-2. (B) The average bone volume/tissue
volume (BV/TV) ratio, (C) the average trabecular thickness
(Tb.Th.) and the average trabecular separation (Tb. Sp.) were
calculated, and the values represent the mean ± SD for n=6;
*p<0.05.
doi: 10.1371/journal.pone.0078551.g003
surface of bone area was, however, remarkably larger in
ectopic bones formed in place of the HA gel/BMP-2+DS or HP
comparing to the HA gel/BMP-2. The sections of ectopic bones
induced by BMP-2 premixed with GAGs exhibited a dense
trabecular structure interwoven with cellular elements than
BMP-2 not complexed. There was no sign of fibrotic tissue in
any area of the ectopic bone.
Furthermore, we analyzed osteocalcin (OC) expression in
the ectopic bone sections (Figure 4, right panel). OC is a
marker of bone formation and ultimately a proof that the tissue
formed is bone. The equal signal was showed in all specimens
at the areas where the bone was previously shown by
Masson’s Trichrome staining. In all groups, we showed that OC
was positively stained not only in osteoblasts, but also in their
surrounding matrix (Figure 4, right panel, inserts). As a positive
control we used a native rat cranium tissue (Figure S2).
4.3: Bone mineral composition.  We then examined
ectopic bone samples by SEM. We showed that ectopic bone
with more interconnected collagen fibers areas was formed
from the gel/BMP-2+DS and gel/BMP-2+HP compared to the
gel/BMP-2 (Figure 5). Furthermore, mapping analysis through
SEM allowed the bone samples to be viewed in terms of their
elemental distribution, with calcium (Ca) and phosphorus (P) .
Backscattered electron mapping on ectopically formed bone for
the three groups illustrated increased distribution of lighter and
darker gray regions. This heterogeneity arises from larger
distributions of higher and lower atomic number elements in the
bone of the gel/BMP-2 (Figure 5). These results were
confirmed by point analyses using elemental mapping of
relative intensity of Ca and P, in which all groups demonstrated
more Ca and P in lighter areas compared to corresponding
darker areas.
4.4: Angiogenesis.  Because osteogenesis is dependent on
blood vessel formation and bone is more likely deposited near
blood vessels [40], we evaluated blood vessel formation in the
ectopic bone after 6 weeks. To confirm that the observed
vessels were maturated, sections were double-labeled with
antibodies directed against the endothelial marker CD31 and
mural cell marker α-SMA. As shown in Figure 4, osteoid in all
groups was formed in the outer ring, which is where we
detected the blood vessels. We observed that CD31-positive
rat blood vessels (red) were penetrating the bone marrow of
newly formed bone (Figure 6). Moreover, autofluorescent
erythrocytes (green) were present in the lumen of all identified
vessels. The autofluorescence of erythrocytes is due to
hemoglobin content [41]. We also detected the presence of an
outer layer of α-SMA-positive cells surrounding the CD31-
positive vessels. Positive fluorescence could not be detected in
sections exposed to the secondary antibody alone (data not
shown). Native rat cranium tissue was used as a positive
control (Figure S2). The CD31 expression patterns were
equally distributed in all three groups. Taken together, these
data demonstrate the presence of efficient host angiogenesis
upon transplantation of all gel constructs.
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Discussion
BMP-2 plays an important role in the early stages of bone
regeneration by recruiting local sources of skeletal progenitors
and by determining their fate towards the osteogenic lineage.
Current methods for therapeutic administration of BMP-2 for
bone repair are associated with unacceptable side effects that
have limited its therapeutic application. For instance, a clinical
trial of alveolar cleft palates in children was prematurely ended
due to a significant amount of postoperative swelling [12,13].
Moreover, patients treated with BMP-2 for posterolateral spinal
fusion were found, during follow-up, to have an increased risk
of cancer [25]. These issues arise due to the high
concentration of the protein required for bone formation that is
a result of the poor stability and short half-life of the protein in
vivo. Molecules, such as BMP-2, that are sensitive and
unstable require a delivery system that is able to protect the
protein against premature degradation, regulate their in vivo
release and provide delivery to the lesion site. We achieved
such a delivery system in the current study using GAGs, such
as dermatan sulfate (DS) and heparin (HP), in a polymer
carrier system that controls the release of active BMP-2 to
significantly enhance bone formation.
Mature BMP-2 is a homodimer that has one heparin binding
site in each of the N-terminal sequences [42,43]. The heparin
binding site consists of several positively charged residues that
are able to interact with ECM components, providing a protein
gradient by restricting the diffusion of free BMP-2 [42]. HP is a
highly sulfated GAG that is known to bind to BMP-2 [33] and
stimulate its activity by protecting it from enzymatic degradation
and the antagonistic actions of noggin [9,34,44]. In contrast,
some in vitro studies indicate that HP may inhibit osteogenic
activity by sequestering BMP-2 on the cell surface and
mediating protein internalization [45]. Animal studies
demonstrated that the incorporation of HP into various
scaffolds [33,34], including HA hydrogels [46], enhanced bone
formation. These results only confirm that HP has a
multifunctional regulatory role, and the range of early
osteogenic markers may not resemble favorable outcomes of
in situ bone formation [38]. The long-term administration of HP
increases the risk of developing osteoporosis, suggesting that
a large dose of HP may not be appropriate for frequent
systemic administrations [47,48]. On the other hand, DS was
recently demonstrated to stimulate progenitor differentiation of
osteoblasts, mediated by BMP-2 [49]. However, its role in
BMP-2-mediated bone formation has not yet been elucidated
[50].
To increase the possibility of direct molecular interactions,
we precomplexed BMP-2 with DS or HP prior to loading into
the HA hydrogel scaffold. Our 30-day in vitro release study
Figure 4.  Six weeks following implantation, the ectopic bone formed by gel/BMP-2+DS, gel/BMP-2+HP and gel/BMP-2 was
evaluated by histology via Masson’s Ttrichrome staining and osteocalcin (OC) immunostaining.  B indicates a trabecular
bone structure; nuclei were stained with DAPI.
doi: 10.1371/journal.pone.0078551.g004
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showed that the presence of DS or HP significantly prolonged
BMP-2 retention while non-complexed BMP-2 released more
rapidly from the gel. The total BMP-2 amount released from
gel/BMP-2+DS and gel/BMP-2+HP was quite similar.
Furthermore, the amount of BMP-2 released from the
constructs determined by ELISA corresponds to the results of
ALP assay with C2C12 cells. This outcome confirmed that
BMP-2 released from the constructs maintained its biological
activity.
Interestingly, the only significant difference in BMP-2 release
from gel/BMP-2+DS and gel/BMP-2+HP was found in the first
24 h of the in vitro cumulative release experiment. Specifically,
the HA hydrogel with BMP-2 precomplexed with DS exhibited a
slightly faster release than that precomplexed with HP. We
therefore performed kinetic SPR analysis that showed that the
BMP-2-DS complex has an affinity slightly less than 10 times
that of the BMP-2-HP complex. The demonstrated increased
binding affinity between BMP-2 and HP compared with that
between BMP-2 and DS may be due to the presence of more
sulfate groups in HP. HP contains a sulfated disaccharide unit
that is able to electrostatically bind to BMP-2 and prolong the
protein stability [9]. Negatively charged sulfate groups in GAGs
bind to positively charged amino groups in different GFs,
including BMP-2 [51]. It was shown that the ability of sulfated
GAGs to stimulate BMP-2 depends on the size and number of
their sulfated groups [38]. The affinity of DS for BMP-2 has not
been defined, although previous studies hypothesized that DS,
like HP, binds to the protein. The possible mechanisms of DS
interactions with BMP-2 are not clear but are likely similar to
Figure 5.  Elemental mapping of the surface of ectopic
bone induced by gel/BMP-2+DS, gel/BMP-2+HP and gel/
BMP-2.  Collagen fibers, secondary electron (SEM), calcium
(Ca) and phosphorus (P) are shown. SEM was performed via
gold coating.
doi: 10.1371/journal.pone.0078551.g005
those of HP interactions (i.e., electrostatic interactions).
Previous studies reported that DS regulates the activity of
FGF-10 and FGF-7 and that the effect is dependent on sulfated
groups and IdoA disaccharides [52]. However, the SPR assay
may detect all possible bonding mechanisms, and according to
some previous reports, the interactions between GAGs and
BMP-2 are complex and may also involve non-sulfated
saccharides [53].
Although the SPR assay demonstrated that DS binds to
BMP-2 with a slightly lower affinity than the binding of HP to
BMP-2, further in vivo evaluation showed that both binding
pairs were physiologically relevant. Micro-CT analysis in
ectopic bone models demonstrated that bone formation was
equal for both the DS- and HP-BMP-2 precomplexed groups
with bone volumes two folds larger than treatment with BMP-2
alone. In 2D images from micro-CT (Figure 3A (lower row)) and
transversal sections stained with Masson’s Trichrome (Figure
4) we noted that bone formed in the ectopic models as oval
rings with bone concentrated at the edges with voids in the
central part of specimen. The remarkable difference was that
ectopic bone formed with treatments of gel/BMP-2+DS or HP
had thicker bone area that penetrated deeper in the middle of
the specimen in contrast to bones induced by gel/BMP-2 alone
(Figure 4). The evaluation of trabecular thickness and
trabecular separation showed that the trabecular bone
structure of the ectopic bone tissue had higher density in the
samples where BMP-2 was precomplexed. The advantage of
more organized trabecular network in bone is apparent since
the spontaneous fractures in osteoporosis occurred due to
weak continuity and connectivity of bone trabeculae that disrupt
force transmission [54]. No areas in the histological sections
demonstrated any unidentified regions i.e. possible
undegraded gel. Furthermore, no giant cells were seen. This
corroborates with earlier studies in our laboratory that showed
complete degradation within 4 weeks [28]. Next we assayed for
osteocalcin, an early marker of bone formation, at the sites
where bone tissue was observed (Figure 4). Furthermore, as
another indication of the quality of ectopic bones we performed
SEM analysis. We observed that the collagen fibers in groups
of gel/BMP-2-DS or HP were more interconnected (Figure 5).
Then the ionic mapping analysis revealed that the ectopic
bones formed by BMP-2 precomplexed with GAGs contained
less calcium (Ca) and phosphor (P) compared to bones
created by BMP-2 not complexed (Figure 6). Both ions indicate
greater content of the mineralized matrix that is a structural
bone component. In addition Ca is crucial for a signal
transduction for bone cell responses [55]. As newly formed
layers of bone contained lower counts of Ca and P compared
to the older layers of bone, it can be concluded that gel/BMP-2
produces bone early on that has mineralized to higher extent
than the bone formed by precomplex BMP-2 in gel. Also, the
wider distribution in the grey intensity of back-scattered
electrons from energy-dispersive spectrometry (EDS) [56] in
samples with gel and precomplexed BMP-2 suggest an
indication of the possible the presence of both older and more
newly formed bone. The elemental mapping showing lower
Ca/P intensity ratio for gel/BMP-2+DS than for gel/BMP-2+HP
may be indicative of a difference in the mechanisms involved in
BMP-2 Complexation and Sequestration Improve Bone
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the bone mineralisation process. Finally we addressed the
presence of angiogenesis within the ectopic bones since
vascularization is critical for bone formation [40]. In all groups
the marrow space of bone was rich with blood vessels with
CD31 positive endothelial cells surrounded by α-SMA positive
myocytes (Figure 6). In addition the blood vessels contained
erythrocytes in the lumen that clearly indicated their
functionality (Figure 6).
The evaluation of ectopic bones engineered by the HA
hydrogel/BMP-2 with or without GAGs suggested that the bone
formation mechanism by those constructs has much in
common with the long bone healing after fracture. The woven
bone begins forming on the hematoma edges and remodel
subsequently in lamellar bone [57]. The ectopic bones at 6th
week post injection might be the result of following sequences:
(i) progenitor cells are attracted to the gel releasing BMP-2 and
differentiate into osteoblasts cells; (ii) providing an adequate
supply of active BMP-2, cells are attracted and migrate toward
the center of the scaffold and produce matrix of collagen and
non-collagenous proteins such as osteocalcin and blood
vessels; (iii) woven bone started mineralization. In human body
complete bone regeneration after injury takes some years and
although the bone formation in rats is more rapid further
monitoring of ectopic bone formation would not give more
useful information. Already the formation of hard callus allows
for patients immobilization that, in turn, give an appropriate
biomechanical stimuli for final bone remodeling [58].
In this study we showed a simple and efficient system that
significantly enhances BMP-2 induced bone repair. We
attributed this outcome to molecular interactions occurring
between active molecules in the gel environment. In Figure S3
we suggested the mechanism of the protein release from gel/
BMP-2+DS or HP and gel/BMP-2. DS, like HP, binds to BMP-2
and the size of the complex might directly slow the diffusion of
BMP-2 and protect the protein from rapid degradation outside
the scaffold. BMP-2 alone in the gel released faster which is
the result of a passive diffusion mechanism [59]. We
demonstrated that BMP-2 interaction with DS is slightly 10
times weaker than those of BMP-2 with HP. The higher affinity
meant that the protein can remain bound for a longer time,
exceeding the duration of GAG-protecting mechanism in the
ECM [42]. However, our hypothesis is that the interplay
between DS and HP with BMP-2 were equally favorable in
vivo. This proved again the well-known statement that in vitro
conditions do not necessarily recapitulate the in vivo setting.
BMP-2 complexed with DS or HP decreases its passive
diffusion and retains its activity in the gel. In addition, in vivo
the cell invasion and degradation of the matrix occurs
simultaneously with the passive diffusion mechanism.
Figure 6.  The cross sections of ectopic bone formed due to gel/BMP-2+DS, gel/BMP-2+HP and gel/BMP-2 were
immunostained with CD31 (red) and α-SMA (green in right panel).  The erythrocytes were visualized by green autofluorescence
(green in left panel). The area showed in middle panel corresponds to area indicated in Figure 5. Cells nuclei were stained with
DAPI (blue). The images are shown merged.
doi: 10.1371/journal.pone.0078551.g006
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Currently it is clear that the wider use of BMP-2 in
regenerative medicine will only be possible with the
development of a concept that enable for the protein dose
reduction in the therapy. In the previous study we reported that
the remarkably improved stability of BMP-2 was achieved in
acidic pH and glass vial comparing to physiological pH and
plastic vial [20]. In another study we showed that BMP-2
stability was enhanced by the presence of HP in the solution
[38]. This study established how DS, equally for HP, has a
protective capacity towards BMP-2 and uses this stabilization
for the incorporation into a gel matrix that provides an
extracellular mimetic reservoir to induce bone formation. Since
the particular HA gel used in this study and rhBMP-2
(InductOS) has already been used separately in patients, and
HP and DS are also already in the clinical use in various forms,
the regulatory approval process for human applications maybe
accelerated. Although we must be aware that in vitro release
and even in vivo assay in rodents cannot precisely simulate
physiological process of human organism. The complexity of
human body requires that the final judgment of certain therapy
utility cannot be made before clinical trial with long follow up.
However, our work highlighted that a broader use of BMP-2 in
the clinic is possible and the strategy that allows that is closer
to achieve.
Materials and Methods
Reported studies using animal subjects were approved
(246/8) by the Experimental Animal Committee of Uppsala
University and conducted according to the Helsinki guidelines
for the use and care of laboratory animals.
1: BMP-2 precomplexed with heparin and dermatan
sulfate loaded in a HA hydrogel scaffold
Recombinant human bone morphogenetic protein-2
(rhBMP-2; InductOs® former Wyeth Europe) was purchased
from Pfizer and reconstituted in the formulation buffer
containing 2.5% glycine, 0.5% sucrose, 0.01% polysorbate 80,
5 mM sodium chloride and 5 mM L-glutamic acid at a
concentration of 1.5 mg/mL according to the manufacturer’s
instructions. GAGs, such as dermatan sulfate (DS;
Calbiochem) and heparin (HP; Sigma-Aldrich), both derived
from porcine intestinal mucosa, were dissolved at 1 mg per mL
of phosphate-buffered saline (PBS, Sigma-Aldrich) and filtered
through a sterile 0.22-µm filter. BMP-2 was mixed and
preincubated with DS or HP for at least 15 min at room
temperature to enable interactions between the growth factor
and GAGs.
The hydrogel components in lyophilized form were
purchased from TERMIRATM (Auxigel; Stockholm, Sweden)
and prepared as follows: component A was prepared by
dissolving aldehyde-modified hyaluronic acid (HAA) at a
concentration of 15 mg/mL in PBS and passing it through a
0.45-µm sterile filter, and component B was prepared by
dissolving polyvinyl alcohol with 5% hydrazide functionality
(PVAH) at a concentration of 5 mg/mL in deionized water,
filtering it through a 0.22-µm sterile filter, and mixing it with
BMP-2 that was earlier precomplexed (or not) with DS or HP.
The final concentrations of the HAA, PVAH, BMP-2 and GAG
components in 1 mL of construct were 9 mg/mL, 1 mg/mL, 25
μg/mL and 125 μg/mL, respectively. According to the
manufacturer, the degree of crosslinking (the average
percentage of polymer repeat units involved in a crosslink) was
5%. One hour after preparation of the solutions they were
combined to form the following constructs: (i) gel/BMP-2+DS,
(ii) gel/BMP-2+HP, (iii) gel/BMP-2 and (iiii) gel alone. For the in
vitro experiments, the construct was formed in the Protein
LoBind tubes (Eppendorf) by vigorous mixing by a shaker. For
the in vivo experiments, components A and B were loaded into
two 1-mL sterile Luer-lock syringes (Becton Dickens Medical)
that were connected via a Luer-lock adapter (Qosina) and
mixed at room temperature 30 times back and forth over a 15
sec period. The gel point was reached after approximately 1
min.
2: In vitro release kinetics of BMP-2 and in vitro
bioactivity assessment of released BMP-2
For the in vitro release experiment, the samples consisting of
0.2 mL of construct containing 5 μg of BMP-2 and 25 μg of DS
or HP, only 5 μg of BMP-2, or hydrogel alone were prepared as
described earlier and placed in 1.5-mL Protein LoBind tubes
(Eppendorf). The samples were allowed to cure for 3 h at room
temperature before being covered with a buffer containing 1
mL of PBS supplemented with 1% bovine serum albumin (BSA,
Sigma-Aldrich), 1 mM EDTA and 10 μg/mL heparin (Sigma-
Aldrich) (which reduces the degradation of BMP-2) and
incubated at room temperature (58). The HA hydrogel without
BMP-2 was used as the negative control. In addition, there was
a BMP-2 control with DS/HP at a corresponding concentration
in PBS solution. Three samples were prepared for each group.
Gel matrices were loaded with BMP-2 and DS or HP; and
their release kinetics was evaluated. Release media (200 µl
PBS, 1% BSA) from wells containing constructs was collected
(50 µl) after the indicated time points and stored in the Protein
LoBinding tubes at -20°C. At each time-point the samples were
replenished with an equal volume of fresh media (50 µl). On
the 30th day, the constructs were treated with a lysis solution
containing 100 μL of 500 units/ml hyaluronidase (Sigma-
Aldrich) in PBS. The amount of BMP-2 in each sample was
determined by a sandwich enzyme linked immunosorbent
assay (ELISA) kit (Human BMP-2 Quantikine; R&D Systems)
as per the manufacturer's instructions. BMP-2 cumulative
release was expressed as a percentage of the starting
concentration. The absorbance of the samples was read at 450
nm and normalized at 570 nm using the Kinetic Microplate
Reader (Molecular Devices). The blank release media was
used as a background correction for BMP-2 levels; and this
value at each time point 15 min, 30 min, 1h, 3h, 6h, 16h, 24h, 2
days, 7 days, 14 days, 21 days and 30 days) was subtracted
from the value obtained from the release media containing gel/
BMP-2with or without DS or HP.
The bioactivity of BMP-2 released from the constructs in vitro
was determined by its capacity to stimulate the alkaline
phosphatase (ALP) activity of the mouse myoblast cell line
C2C12 purchased from the American Type Culture Collection
(ATCC–LGC Standards, Sweden). C2C12 cells were employed
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because there is a confirmed correlation between the ALP
activity and amount of bioactive BMP-2 in this particular cell
line [3,9]. The cells were cultured in Dulbecco’s modified
Eagle’s medium (DMEM, Gibco) supplemented with 10% (v/v)
fetal bovine serum (Gibco) and 100 U ml-1 penicillin and
streptomycin (Gibco) at 37°C in a 5% CO2-95% air
atmosphere. The cells were seeded at 5x103/mL in 96-well
plates in the culture media. After 24 h, the culture media was
changed to media containing 10 vol% of release media that
was obtained in the in vitro release experiment. After 48 h, the
cells were washed with PBS and lysed by two freeze-thaw
cycles at -80°C and 37°C (30 and 20 min for the first and
second cycles, respectively). The ALP activity in this extracted
solution was determined using the p-nitrophenol (pNP)
concentration obtained from 100 µL of substrate (p-nitrophenyl
phosphate; Sigma-Aldrich) in 0.1 M glycine, 1 mM MgCl2, and 1
mM ZnCl2 at a pH of 10.4 at 37°C. After 20 min, 50 µL of 0.1 M
NaOH was added to stop the reaction. The absorbance was
read at 405 nm, which corresponds to pNP concentrations
determined using the Kinetic Microplate Reader (Molecular
Devices). Each ALP activity measurement was normalized to
the total sample protein content quantified using the NanoDrop
(ND-1000, Thermo Scientific). The experiments were
performed in triplicate.
3: Kinetic interactions between BMP-2 and DS/HP
To determine the binding affinity and kinetics between
BMP-2 and DS or HP, the interaction was measured using
Biacore™ X100 and SA sensor chips that are pre-coated with
streptavidin (GE Healthcare). A solution of 20 mM phosphate-
buffered saline, 2.7 mM KCl, 137 mM NaCl, and 0.05%
surfactant P20 (pH 7.4) was prepared from a stock solution
(10X PBS-P+, GE Healthcare) and used as running buffer.
After docking the SA sensor chip and priming the instrument
with running buffer, the chip was preconditioned with three
injections (1 min each) of 40 mM NaOH (GE Healthcare) and 1
M NaCl (Merck) (NaOH/NaCl) following the recommendations
provided by the Biacore X100 software. Biotinylated HP from
porcine intestinal mucosa (Sigma-Aldrich) and biotinylated DS
from porcine intestinal mucosa were prepared as described
elsewhere [36] (gift from Silesia University) and dissolved in 10
mM sodium acetate (pH 5.5). DS or HP was immobilized by
injecting approximately 1 µg/mL of solution into flow cell 2.
Flow cell 1 was used for the reference subtraction of all signals.
Immobilization levels were kept relatively low, below 20 RU, to
minimize the possibility that BMP-2 binds to two HP or DS
molecules simultaneously. In each binding cycle, BMP-2 was
injected for 150 s, followed by the monitoring of dissociation for
300 s while running buffer was flowing over the surface at a
flow rate of 30 μL/min. Each association/dissociation step was
followed by 30 s of regeneration with NaOH/NaCl and a 1-min
stabilization period before the next binding cycle started. An
initial series of 3 buffer injections was performed to equilibrate
the system. BMP-2 binding was monitored using a three-fold
dilution series with six concentrations ranging from 0.2 to 50
nM. Before, during and after the dilution series, buffer solutions
were injected, and the average of these three “blank” cycles
was used for a second reference subtraction of all binding data.
For the kinetic analyses, data were globally fit to a 1:1
interaction model to obtain binding parameters. Analysis of the
binding kinetics was performed using Biacore™ T200
evaluation software (GE Healthcare). The apparent equilibrium
dissociation constant (Kd) was calculated as the ratio of kd/ka.
4: Efficacy of in vivo bone formation
4.1: Study design.  Six adult male Sprague-Dawley rats
(Taconic M&B, Lille Skensved, Denmark), aged 9-10 weeks,
weighing approximately 280-300 g, were anesthetized using
isoflurane (4,5% induction, 2.5% maintenance; Forene®,
Abbott Scandinavia), starting with flow rates of 4 L/min oxygen
and 4 L /min in isoflurane in an induction chamber and then by
mask at flow rates of 1.5 L/min oxygen, 1.5 L/min air and 3 /min
isoflurane. After shaving, the lumbar region was disinfected
with three washes of 70% ethanol. Each construct of 0.2 mL in
volume (n=6) was injected subcutaneously with a 21-G needle
at a minimum depth of 15 mm. The HA hydrogels did or did not
contain 4 µg of BMP-2 and 20 μg of DS or HP per injection.
The HA hydrogel without BMP-2 or GAGs was considered a
negative control. Immediately after the intervention, animals
received 0.05 mg/kg buprenorphine (Temgesic, Schering-
Plough) subcutaneously, after which time the animals had no
signs of pain or distress. The animals were housed with two
rats per cage with 12/12 h light/dark cycles in a controlled
environment (temperature 22°C and humidity 45 ± 10%) with
ad libitum access to food and water. Six weeks after the
injection, the rats were sacrificed via CO2 asphyxiation, and
ectopic ossification which occurred in the upper region of the
back were harvested. The bone samples were fixed in 4%
paraformaldehyde in PBS, which was replaced with 70%
ethanol after 24 h at room temperature.
4.2: Determination of bone volume.  The ectopic bone
formation was evaluated by micro-CT using a Skyscan 1072
system (Kontich) with 100 kV/98 µA X-ray source. For
quantitative 3D analysis, the specimens were placed vertically
onto the sample holder of the micro-CT imaging system.
Subsequently, a high-resolution scan was performed at a final
resolution of 14.53-μm (20x magnification; 3.9-s exposure time;
1-mm filter applied). Then, using Nrecon V1.4 (SkyScan), a
cone beam reconstruction was performed on the projected
files. The bone volume-to-total tissue volume (BV/TV) ratio,
trabecular thickness (Tb. Th) and trabecular separation (Tb.
Sp.) of the ectopic bone samples was calculated by
morphometric analysis with segmentation thresholds of 41-159
(CT analyzer; software version 1.10.1.0, SkyScan). Data from
each group are expressed as mean ± standard deviation (n=6).
Finally, using a 3D creator software (3D-DOCTOR 4.0, Able
Software Corp.), 3D reconstructions of the samples were also
obtained.
4.3: Bone structure assessment using histology.  The
specimens stored in 70% ethanol were further processed for
evaluation by histology. The ectopic bones were completely
decalcified using an electrophoresis system (Tissue-Tek Miles
scientific, Histolab) with formic acid, dehydrated, and
embedded in paraffin wax. Serial cross sections were cut from
the middle part of the specimens with a microtome at a
thickness of 5 μm, deparaffinized and stained using Masson’s
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Trichrome (Merck). The histological sections were
photographed using a bright-field microscope (Eclipse TE
2000U, Nikon).
4.4: Bone structure assessment using electron
microscopy.  For the SEM analysis, undecalcified samples
were embedded in poly(methylmethacrylate) [21]. Briefly, the
samples were immersed in methylmethacrylate (MMA) for 24 h
at 4°C. Then, they were incubated in MMA with 2% benzoyl
peroxide (BP) for 3 days at 4°C. Finally, they were placed in a
solution of 100 mL of MMA containing 4 g of BP and 25 mL of
dibutylphthalate and stored in sealed glass vials at 4°C for 7
days and then 14 days at room temperature. The sample
blocks were polished through a series of silicon carbide paper
ranging from P220 to P2400 (Struers), corresponding to a grain
size range of 60 to 5 µm. Once the surfaces were sufficiently
even and smooth, they were double-coated with gold and
cemented on SEM stud supports using carbon cement
(Struers). SEM of the samples was performed with an
INSPECT F (FEI,England) instrument at 10 keV
(magnifications and other details are provided in the images
themselves). Using the INCA software, images were further
analyzed by elemental mapping of the sample surfaces at 10
keV with an objective aperture of 3 and spot size of 5.0. The
data were collected at a rate of 14 frames per sample using
secondary electrons detection.
4.5: Evaluation of osteogenic and angiogenic
markers.  Paraffin sections were immunostained with primary
antibodies specific for rat osteocalcin (OC; Santa Cruz
Biotechnology), rat CD31 (BD) and rat alfa-smoth muscle actin
(α-SMA; Dako). The sections were placed in a Tris/EDTA
solution (pH 9; Dako), incubated at 95°C for 20 min, washed
with PBS and blocked in a 12% BSA solution. Slides were then
labeled with the primary antibodies, namely OC (1:50), CD31
(1:50), and α-SMA (1:100), and diluted in PBS containing 12%
bovine serum albumin (BSA). After overnight incubation at 4°C,
the sections were washed three times for 5 min in PBS and
blocked for additional 15 min. To visualize the primary
antibody, TRITC- or FITC-conjugated polyclonal goat F(ab’)2
fragments directed at mouse or rabbit immunoglobulins (Dako)
were added to the sections. Slides were washed three times for
5 min in PBS. Some sections of cranial bone (positive control)
and some sections not treated with the primary antibody
(negative control) were used. Finally, the slides were incubated
for 5 min in PBS containing 1 µg/ml Hoechst 33342 (Sigma),
rewashed with PBS, and mounted with Dako mounting solution
(Dako). Images were taken with a DXM1200F digital camera
connected to a Nikon Eclipse TE2000-U inverted microscope.
The device is equipped with Hoechst 33342, FITC, and TRITC
filter sets (Nikon AG, Switzerland; Software: Nikon ACT-1 vers.
2.70). Images were processed with Photoshop 7.0 (Adobe
Systems Inc.).
5: Statistical analysis
Statistical analysis was performed with PASW Statistics 16.0
(SPSS Inc.). Student’s t-test was used to analyze the
significant differences between all groups based on the
consideration that a p-value less than 0.05 was significant.
Conclusions
In our study, first we investigated the ability of DS and HP to
protect BMP-2 and control its release from a hydrogel scaffold
in vitro. The release study showed that BMP-2 precomplexed
with DS or HP provided prolonged protein release compared
with the same system with non complexed BMP-2. Although
HP showed a slightly higher affinity to BMP-2 than DS, both
constructs yielded equal volumes of ectopic bone formation.
The amount of bone formed with precomplexed BMP-2 was
two times larger and exhibited more abundant trabecular
network compared with the HA hydrogel with BMP-2 alone. Our
findings further highlighted that molecular interactions occurring
between BMP-2 and DS are as important as those between
BMP-2 and HP, as well as that by modulating the protection
and delivery of the growth factor, significant enhancements in
bone formation can be achieved. This knowledge can
accelerate development of alternative approaches for safer
bone fracture treatment. Presented strategy uses starting
materials and components that are in clinical use today. This
strategy may lead to decrease required dose of BMP-2
reducing the risks of side effects and therapy costs.
Supporting Information
Figure S1.  BMP-2, either alone or precomplexed with
dermatan sulfate (DS) or heparin (HP), was added to
polyvinyl alcohol (PVAH) and hyaluronic acid aldehyde
(HAA). All components were mixed to form a gel construct.
(TIF)
Figure S2.  As a control, the cross sections of rat cranium
was immunostained with osteocalcin (OC, red), CD31 (red)
and α-SMA (green). The erythrocytes were visualized by
green autofluorescence. Cell nuclei were stained with DAPI
(blue). The images are shown merged.
(TIF)
Figure S3.  A schematic representation showing the
mechanism of the BMP-2 release process. The low rate of
diffusion of BMP-2 protected by complexation using dermatan
sulfate or heparin (gel/BMP-2+DS or HP) in comparison with
the higher rate of diffusion of non-complexed BMP-2 (gel/
BMP-2).
(TIF)
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